William Blair Brokers Lower Earnings Estimates for RARE

Key Points

• William Blair has lowered its Q4 2026 earnings per share estimate for Ultragenyx Pharmaceutical from $0.99 to $0.94, while maintaining an "Outperform" rating and $65.00 price target for the stock.
• Ultragenyx reported a Q2 earnings per share of ($1.17), exceeding the consensus estimate of ($1.27) and showing a year-over-year revenue increase of 13.2% to $166.50 million.
• Recent analyst activity shows mixed ratings, with one analyst rating the stock as "hold" and eleven as "buy," contributing to an average rating of "Moderate Buy" with a consensus target price of $82.17.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at William Blair reduced their Q4 2026 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a report issued on Tuesday, August 5th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will earn $0.94 per share for the quarter, down from their prior forecast of $0.99. William Blair has a "Outperform" rating and a $65.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 214.21% and a negative net margin of 87.34%. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the prior year, the firm earned ($1.52) EPS. The business's revenue for the quarter was up 13.2% compared to the same quarter last year.

RARE has been the topic of a number of other research reports. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target on the stock in a research report on Monday, July 28th. Morgan Stanley reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Cantor Fitzgerald reduced their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Wedbush cut their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $82.17.

Ultragenyx Pharmaceutical Stock Up 1.1%

Shares of RARE opened at $28.36 on Thursday. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $60.37. The business has a 50-day simple moving average of $33.59 and a two-hundred day simple moving average of $36.96. The stock has a market cap of $2.68 billion, a PE ratio of -5.15 and a beta of 0.25.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently bought and sold shares of RARE. Price T Rowe Associates Inc. MD boosted its position in shares of Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after purchasing an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after purchasing an additional 965,919 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after purchasing an additional 5,400 shares in the last quarter. Deutsche Bank AG boosted its holdings in Ultragenyx Pharmaceutical by 0.5% in the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock worth $61,611,000 after buying an additional 8,385 shares during the period. Finally, Invesco Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 1.5% during the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after buying an additional 25,487 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.